Taken together, we assume that ARID1A-deficiency (ARID1A truncating mutations and/or expression loss) is not a suitable predictive biomarker for EZH2 inhibitor treatment response in urothelial bladder cancer. The gene discussed is EZH2; the disease is bladder transitional cell carcinoma.